ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

The launch of Journavx represents Vertex’s entry into the pain management market, a move that could significantly diversify its revenue streams. The non-opioid nature of Journavx is expected to ...

Vertex has established itself as a dominant player in the CF market, with a portfolio of transformative medicines that have significantly improved patient outcomes. The company’s recent approval of ...

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...